Foundation Medicine

Executive Summary

Foundation Medicine (FMI) is a leading precision medicine diagnostics company providing comprehensive genomic profiling (CGP) to guide cancer treatment. Its FDA-approved tests, including FoundationOne®CDx (tissue) and FoundationOne®Liquid (blood), identify actionable genomic alterations to enable personalized therapy selection for patients. By integrating CGP with clinical decision support, FMI serves oncologists and biopharmaceutical partners, accelerating companion diagnostic development and drug matching. As a majority-owned subsidiary of Roche since 2018, FMI benefits from deep resources while maintaining operational independence, positioning it as a critical enabler of precision oncology globally. In the evolving landscape of liquid biopsy and multi-omics, FMI recently launched FoundationOne®RNA to capture gene fusions and expression profiles, complementing its DNA-based portfolio. The company continues to expand test indications, gain regulatory approvals, and secure biopharma collaborations for companion diagnostics. However, as a private entity, growth is largely driven by strategic partnerships and incremental test adoption rather than public market catalysts. With a robust installed base and Roche’s backing, FMI is well-positioned to maintain leadership in CGP, though near-term upside may be moderate.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of FoundationOne®Liquid CDx for additional solid tumor types75% success
• Q3 2026New biopharma companion diagnostic partnership for a late-stage oncology drug60% success
• Q1 2027Expansion of FoundationOne test portfolio into a new major market (e.g., NMPA approval in China)40% success